A Multicenter, Placebo-controlled Clinical Study of Berberine Hydrochloride in Preventing Recurrence and Carcinogenesis After Endoscopic Removal of Colorectal Adenomas：6-year Retrospective Follow-up Data

Colorectal cancer (CRC) is a common malignancy of the digestive tract, which constitutes a major public health burden. Almost 90% of CRC cases progress from precursor adenomatous polyps through adenoma-carcinoma sequence. Endoscopic detection and removal of colorectal adenoma (CRA) could reduce the incidence and mortality risk of CRC, but the recurrence rate is still high. Therefore, chemoprevention is quite important, not only solve the urgent public health problem, but also be cost-effective.
In 2020, the investigators published a multicenter, randomized, double-blind, placebo-controlled clinical study (NCT02226185) in the Lancet Gastroenterology & Hepatology. The result concluded that oral BBR for 2 years significantly reduced recurrence after endoscopic removal of CRA (RR 0.77, 95%CI 0.66-0.91; p=0.001). BBR also has a significant preventive effect on all polypoid lesions, including adenomas and serrated lesions (adjusted RR 0.78, 95%CI 0.66-0.91; p=0.002) . Does BBR still have a long-term protective effect on the recurrence of CRA after discontinuation? That's what the investigators concerned.
The present study is performed to observe and compare retrospectively the recurrence rate of CRAs in patients of the original BBR RCT study (NCT02226185) within 6 years after discontinuation of medication, including the overall recurrence rate of traditional adenomas within the first year, 1-3 years, 3-6 years, and the entire follow-up period of 6 years. The aim is to evaluate the long-term efficacy of BBR in preventing recurrence and carcinogenesis after endoscopic resection of CRAs.

开始日期2024-10-04

申办/合作机构

上海交通大学医学院

[+4]

NCT06530069 / RecruitingN/AIIT

Exploring the Risk Factors of Otomycosis: A Case-Control Study

The goal of this observational study is to explore the risk factors of fungal otitis externa in the fungal otitis externa patients The main question it aims to answer is:
What behaviors lead to the occurrence of fungal otitis externa? Participants will complete a detailed questionnaire survey. If there is a comparison group: Researchers will compare the healthy group and the disease group to see if there are any differences.

开始日期2024-08-01

申办/合作机构

厦门大学附属中山医院

100 项与厦门大学附属中山医院相关的临床结果

登录后查看更多信息

0 项与厦门大学附属中山医院相关的专利（医药）

登录后查看更多信息

826

项与厦门大学附属中山医院相关的文献（医药）

2025-01-01·BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

PRR promotes hypertensive renal injury by activating Wnt/β-catenin signaling and inflammation infiltration in mice

Article

作者: Wang, Dedong ; Lin, Mengjiao ; Chen, Gewenhan ; Ou, Juanjuan ; Chen, Yanlan ; Xiao, Liangxiang ; Zhou, Yanni

Hypertension stands out as a substantial independent risk factor in the progression of chronic kidney disease; however, the exact pathological mechanisms remain elusive. Our preliminary studies find that Wnt/β-catenin control renin-angiotensin system (RAS) expression, thus playing an important role in the pathogenesis of hypertension and renal fibrosis. As an integral component of the RAS, the (pro)renin receptor (PRR) plays a crucial role in the activation of the RAS and hypertension. Recent studies suggest a reciprocal relationship between PRR and Wnt/β-catenin signaling, potentially contributing to hypertensive renal fibrosis development. To assess the role of PRR in mediating hypertensive nephropathy, we manipulated this signaling by over expression of PRR ligand or blockade of PRR by siPRR. In vivo, PRR induction promoted hypertension, proteinuria, renal fibrosis, inflammatory response and β-catenin activation in Ang II induced hypertension mice. Conversely, blockade of PRR inhibited Ang II mediated hypertension, renal fibrosis and inflammation. In vitro, PRR over expression renal tubular cells exacerbated the Ang II induced fibrotic response and inflammation. Moreover, PRR was upregulated in hypertensive nephropathy patients, and correlated with renal function and renal fibrosis. These results indicate that PRR interact with Wnt/β-catenin signaling promote the progression of hypertensive nephropathy. PRR could be served as a biomarker for the diagnosis and treatment of hypertensive renal fibrosis.

2024-12-31·Virulence

Throat microbiota drives alterations in pulmonary alveolar microbiota in patients with septic ARDS

Article

作者: Wang, Chang-Song ; Lv, Jia-Feng ; Yu, Kai-Jiang ; Chong, Yang ; Zhao, Ming-Yan ; Wang, Xi-Bo ; Wang, Yi-Qi ; Li, Yue ; Liu, Yan-Qi ; Zhang, Jian-Nan ; Luo, Pei-Yao ; Kang, Kai ; Li, Na-Na ; Man, Ming-Yin ; Zhang, Qian-Qian ; Zhou, Yang ; Peng, Ya-Hui ; Wang, Lei ; Luan, Fei-Yu

OBJECTIVES:

The translocation of intestinal flora has been linked to the colonization of diverse and heavy lower respiratory flora in patients with septic ARDS, and is considered a critical prognostic factor for patients.

METHODS:

On the first and third days of ICU admission, BALF, throat swab, and anal swab were collected, resulting in a total of 288 samples. These samples were analyzed using 16S rRNA analysis and the traceability analysis of new generation technology.

RESULTS:

On the first day, among the top five microbiota species in abundance, four species were found to be identical in BALF and throat samples. Similarly, on the third day, three microbiota species were found to be identical in abundance in both BALF and throat samples. On the first day, 85.16% of microorganisms originated from the throat, 5.79% from the intestines, and 9.05% were unknown. On the third day, 83.52% of microorganisms came from the throat, 4.67% from the intestines, and 11.81% were unknown. Additionally, when regrouping the 46 patients, the results revealed a significant predominance of throat microorganisms in BALF on both the first and third day. Furthermore, as the disease progressed, the proportion of intestinal flora in BALF increased in patients with enterogenic ARDS.

CONCLUSIONS:

In patients with septic ARDS, the main source of lung microbiota is primarily from the throat. Furthermore, the dynamic trend of the microbiota on the first and third day is essentially consistent.It is important to note that the origin of the intestinal flora does not exclude the possibility of its origin from the throat.

2024-12-31·Hematology (Amsterdam, Netherlands)

Hub genes and associated drugs for multiple myeloma with 1q21+: identified by bioinformatic analysis

Article

作者: Chen, Yamei ; Xu, Zhiqiang ; Yu, Jieni

While 1q21+ was common genetic alteration and found to have adverse effect on prognosis, the underlying genes remain unclear. Identification of related genes may provide additional help for rational intervention. The microarray dataset GSE2658 associated with MM was downloaded from the Gene Expression Omnibus (GEO) database. The differentially expressed genes (DEGs) were obtained, and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed to annotate their functions. The hub genes were derived from the combined results of up-regulated DEGs and weighted gene coexpression network analysis (WGCNA). The receiver operating characteristic (ROC) curves of hub genes were plotted to evaluate correlation with 1q21+. Survival analysis and drug-gene interaction of hub genes were performed separately to find the prognostic value and potential targeted drugs. A total of 55 DEGs were identified. GO and KEGG pathway analyses suggested that the DEGs were related to several pathways of cell proliferation. NVL, IL6R, DUSP23 were proven to be highly correlated with 1q21+ and have adverse effects on prognosis. IL6R, DUSP23 were matched to known interaction-drug. This study revealed potential roles of hub genes in the pathogenesis and progression of MM with 1q21+, further investigations are needed to elucidate the mechanisms.

项与厦门大学附属中山医院相关的新闻（医药）

2024-11-05

·华森制药

华森制药携甘桔冰梅片参加中国中西医结合学会耳鼻咽喉科专业委员会第二十次学术年会

2024年11月1日-3日，中国中西医结合学会耳鼻咽喉科专业委员会第二十次学术年会在上海隆重召开。本次会议由中国中西医结合学会主办，中国中西医结合学会耳鼻咽喉科专业委员会承办，中国中西医结合耳鼻咽喉科杂志、复旦大学附属眼耳鼻喉科医院协办，来自全国各地的中西医结合领域的专家学者、临床医师及科研人员共襄盛会。本次大会以“融合创新，共谋发展”为主题，围绕中西医结合在耳鼻咽喉科疾病诊疗中的新理念、新技术和新方法进行深入探讨。大会精心策划了一系列丰富多彩的学术交流活动，包括：本领域评出的十大新进展；邀请国内知名专家学者分享最新的研究成果和临床经验的专题讲座；为年轻医生和研究人员提供展示自己工作的平台，鼓励创新思维碰撞的青年论坛；通过直观的视频资料，展示手术技巧和治疗方法，促进实践技能提升的视频展示；精选高质量的学术论文，进行现场交流和讨论，激发学术灵感的大会发言；以及实时展示精细的解剖操作，提高临床操作的精准性和安全性的解剖直播。北京中医药大学东方医院刘大新教授作《中西医结合任重道远》学术报告广州中医药大学第一附属医院阮岩教授作《中西医结合防治变应性鼻炎研究与应用》学术报告复旦大学附属眼耳鼻喉科医院余洪猛教授作《鼻咽癌外科创新体系建设新进展》学术报告成都中医药大学附属医院田理教授作《经方防治鼻鼽（变应性鼻炎）循证研究进展》学术报告辽宁中医药大学附属医院冷辉教授作《中国特色的眩晕医学学科建设》报告厦门大学附属中山医院庄佩耘教授作《声带运动障碍相关疾病精准诊疗体系的研发及推广应用》报告云南省中医医院黄春江教授作《从中医痹症论治喉痹》报告广州中医药大学第一附属医院何伟平教授作《经方治疗耳眩晕的临床应用》报告湖北省中医院邓可斌教授作《卫气营血辩证在耳鼻喉科的运用》报告华森制药携甘桔冰梅片、苍耳子鼻炎胶囊等产品积极参与了本次会议，向参会专家介绍了产品的临床研究新进展，并分享来自临床一线的用药经验，为临床医师提供更多的诊疗参考。与会专家对甘桔冰梅片的临床价值纷纷表示肯定，对华森新品苍耳子鼻炎胶囊也表示充满期待。甘桔冰梅片为耳鼻喉专科特色产品，国家中药保护品种，国家医保品种，入选国家首批《100个基于评价证据疗效独特的中药品种》（位列40）。先后被《中医耳鼻喉科临床诊疗指南》、《新冠感染成人居家中医药健康管理专家共识》、《2023年春季成人流感中医药防治专家共识》等十余项指南/共识收录并推荐。甘桔冰梅片上市近二十年，积累了大量的临床研究数据及人用经验，该药治疗咽喉疾病可抗炎镇痛、抗菌、抗病毒、止咳化痰、抗变态反应，有效缓解咽痛、咽干、咽粘膜充血、声音嘶哑等症状，其疗效与安全性深得专家和患者的一致好评。

2024-10-29

·华森制药

华森制药携甘桔冰梅片参加2024年广东省中西医结合学会嗓音专业委员会学术大会

为了进一步促进广东省中医、中西医结合嗓音专业的发展，提高省内嗓音专业中医、中西医结合学术水平。2024年10月25-27日，广东省中西医结合学会嗓音专业委员会换届大会、学术年会暨广东省名中医李云英教授学术思想传承学习班在广东中山市召开。同期举办了言语与听力论坛、中西医结合治疗内耳疾病理论创新与特色技术培训班。身为东道主的中山市中医院党委书记赖海标进行了开幕欢迎致辞并对中山市中医院的近几的发展成果和未来几年的规划做了汇报。广东省中医院、广东省中西医结合嗓音专业委员会主任委员李云英主委进行了开幕致辞广东省中医院、广东省中西医结合嗓音专业委员会副主任委员陈文勇主委进行了开幕致辞会议邀请了国内中西医领域的32位知名专家授课，就嗓音医学、听力言语医学的最新研究进展、行业前景、中西医结合治疗嗓音与听力言语疾病的经验分享等进行阐述，共同探讨嗓音、听力言语健康与疾病防治的最新研究成果与临床应用。大会分为主会场、护理专场、言语听力专场。本次会议以权威讲座、学术交流、实操工坊相结合的方式进行，会议议程涵盖了嗓音医学、听力言语疾病的基础研究、中西医临床诊断与治疗技术、嗓音言语康复、嗓音耳部疾患保护等多个方面。会议吸引了超过400余名专业人士参与，会场热烈和谐、精彩纷呈，与会者普遍认为本次会议内容丰富、形式多样，对嗓音医学领域的研究与临床实践具有重要的指导意义。厦门大学附属中山医院庄佩耘教授作《嗓音疾病的诊疗原则及嗓音医学的前景》学术报告河南中医药大学第一附属医院梅祥胜教授作《钢琴在嗓音病诊疗中的应用》学术报告深圳市中医院刘元献教授作《咽喉疾病的经方应用初探、耳鸣耳聋--如何辩证使用中成药》报告广东省中医院(总院)耳鼻咽喉头颈科主任朱任良教授作《皮瓣在耳鼻咽喉头颈手术修复的应用》报告本次嗓音学术会议的成功举办，为嗓音医学、听力言语疾病领域的专家学者提供了一个高水平的学术交流平台，促进了嗓音医学、听力言语疾病研究与临床实践的深入发展。华森制药携甘桔冰梅片、苍耳子鼻炎胶囊等产品参加了本次会议，同与会专家进行了产品的介绍和交流，获得了专家的认可。甘桔冰梅片为耳鼻喉专科特色产品，由甘草、桔梗、冰片、乌梅等八味中药组成，具有清热解毒、消肿止痛、宣肺化痰、生津润燥的功效，治疗咽喉疾病可抗炎镇痛、抗菌、抗病毒、止咳化痰、抗变态反应，有效缓解咽痛、声音嘶哑、咽干灼热、咽黏膜充血等问题。被纳入多项临床诊疗指南/专家共识推荐用药，并入选国家《100个基于评价证据疗效独特的中药品种》。

高管变更

2024-10-28

·PRNewswire

MitrAssist Lifesciences Announces Promising Initial Clinical Results for SIKELIA™ Polymeric Heart Valve at TCT Conference 2024

WASHINGTON, Oct. 28, 2024 /PRNewswire/ -- MitrAssist Lifesciences, a leader in innovative cardiovascular medical devices, today unveiled the initial clinical results of its groundbreaking new product, SIKELIA™, during the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Conference held in Washington, D.C. The early findings demonstrate promising potential in improving outcomes for patients suffering from severe symptomatic aortic stenosis. SIKELIA transthoracic heart valve (THV) is designed for transcatheter aortic valve implantation (TAVI) procedure. It features a unique polymer leaflet design which allows enhanced durability and reduced thrombogenicity and calcification while lowering production costs. SIKELIA THV is also fully retrievable at 100% frame expansion allowing reposition in case of misplacement. The clinical trial results, involving 12 patients from 4 centers, with a maximum follow up of 27 months, revealed favorable safety and performance 1-year outcomes. A significant improvement in hemodynamic performance was demonstrated by reduced mean pressure gradient and increased effective orifice area. The functional status as assessed by NYHA class, 6-minute walk test and KCCQ score was improved significantly in all measures. In addition, at 1 year follow-up, normal leaflet mobility without hypoattenuated leaflet thickening (HALT) or calcification was confirmed in all patients. "The initial clinical results of SIKELIA™ mark a significant milestone in our mission to transform patient care," said Peggy Wang, CEO of MitrAssist. "We are excited about the potential SIKELIA has to improve outcomes for patients suffering from severe aortic stenosis. SIKELIA capabilities and these initial results provide a foundation for the next phases of clinical testing, and we look forward to continuing our work to bring this innovation to physicians and patients around the world." The presentation at the TCT Conference attracted the attention of top physicians, industry leaders and medical professionals eager to explore more about the product. Dr. Xiaochun Zhang from Zhongshan Hospital and the Shanghai Medical College of Fudan University presented the initial results of this first-in-human, prospective, single-arm, multicenter study, on behalf of the study investigators. In addition to Zhongshan Hospital, the participating centers included Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences, Xiamen Cardiovascular Hospital Xiamen University and Zibo Central Hospital. "The initial outcomes we are seeing from SIKELIA™ could represent a real breakthrough in the TAVR field," said Prof. Junbo Ge from Zhongshan Hospital, principal investigator of the clinical trial. "The potential for improving patients' outcomes is immense, and we are eager to continue gathering data and enhancing the application of this technology. These results are just the beginning, and they pave the way for more comprehensive studies in the near future." For further information, please visit MITRASSIST LIFESCIENCES LIMITED is a leading global company for innovative cardiovascular medical devices, focusing on providing advanced diagnostic and therapeutic solutions for cardiovascular patients. The company product line covers a wide range of applications in the cardiovascular field from structural heart disease to heart failure. MitrAssist is dedicated and committed to innovation and improving patient care. Logo: SOURCE MitrAssist Lifesciences WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED